Pasithea Therapeutics Corp. cotiza a 0.42 USD y tiene una capitalización bursátil de $14M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhib…
| Periodo | 2026-05 | 2026-03 | 2023-08 | 2023-05 |
|---|---|---|---|---|
| Real | $-0.12 | $-0.89 | $-2.84 | $-2.47 |
| Estimado | $-0.45 | $-0.18 | $-3.40 | $-3.40 |
| Sorpresa | +73.3% | -394.4% | +16.5% | +27.4% |
| Métrica | KTTA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -37.0% | -40.4% | +3.4% |
| ROA | -33.9% | -32.0% | -1.9% |
| Current Ratio | 11.35 | 2.84 | +8.51 |
| Debt / Equity | — | 0.28 | — |